Objective

2

To explore the clinical efficacy of Osteoking combined with non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis based on real-world data and provide a basis for clinical medication.

Method

2

From May 2020 to December 2021， the data of a total of 1 002 patients with knee osteoarthritis who did not undergo knee joint replacement surgery was collected through the registration method. 952 patients were ultimately included， including 133 cases orally taking Osteoking combined with non-steroidal anti-inflammatory drugs as the observation group and 73 cases orally taking non-steroidal anti-inflammatory drugs alone as the control group. Statistical analysis was conducted on the baseline data， VAS scores， WOMAC scores， and other items. The visit point is the 4

th

and 8

th

weeks after registration. In order to further elucidate the clinical efficacy of Osteoking combined with non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis， the effective components of Osteoking and the relevant gene sets of non-steroidal anti-inflammatory drugs and knee osteoarthritis were obtained through network pharmacology methods and retrieval in bone injury cross database， TCMSP， and other databases. Venn analysis was performed on the relevant gene sets， and a PPI network diagram was constructed. Then key core targets were screened out， and enrichment GO and KEGG enrichment analyses were conducted.

Result

2

The VAS score of the observation group decreases by an average of （-2.79±1.206） scores in the 4

th

week， which is better than the control group ［（-2.73±1.575） scores，

P

<

0.05］. The VAS score of the observation group decreases by an average of （-3.97±1.308） scores in the 8

th

week， which is better than the control group ［（-3.89±1.822） scores，

P

<

0.05］. The total WOMAC score of the observation group decreases by an average of （-52.07±21.677） scores points in the 8

th

week， which is significantly better than the control group ［（-46.75±25.368） scores，

P

<

0.05］. The observation group has an average decrease of （-10.99±4.229） scores in WOMAC （pain） score in the 8

th

week， which is better than the control group ［（-10.03±5.535） scores，

P

<

0.05］. The observation group has an average decrease of （-1.49±2.901） in WOMAC （stiffness） score in the 4

th

week， which is better than the control group ［（-0.92±1.998） scores，

P

<

0.05］， and the observation group has an average decrease of （-1.90±3.200） scores in WOMAC （stiffness） score in the 8

th

week， which is better than the control group ［（-1.26±2.230） scores，

P

<

0.05］. The observation group shows an average decrease of （-39.17±16.562） scores in WOMAC （joint function） score in the 8

th

week， which is significantly better than the control group ［（-35.47±20.098） scores，

P

<

0.05］. According to network pharmacology analysis， the core network target of Osteoking in treating knee osteoarthritis is manifested as regulating signal pathways such as signal transduction transcription activator 3（STAT3）， vascular endothelial growth factor A（VEGFA）， tumor necrosis factor （TNF） to regulate cell signaling， angiogenesis， chondrocyte proliferation and migration， and inflammatory cells， thereby inhibiting inflammatory reactions， reducing damage， and delaying the development of the disease.

Conclusion

2

After a 4-week and 8-week course of treatment for knee osteoarthritis with Osteoking combined with non-steroidal anti-inflammatory drugs， there is a significant therapeutic effect on relieving pain and joint stiffness and improving joint function. In network pharmacology， Osteoking is involved in regulating inflammatory factors， metabolic response-related biological processes， the proliferation and apoptosis of chondrocytes， etc. in the treatment of knee osteoarthritis， resulting in anti-inflammatory and analgesic effects and improving joint mobility and joint stiffness. Therefore， it is worthy of clinical promotion and application.